The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study

Table 4

Number of new cases, population at risk, estimated hazard ratios (HR), and 95% confidence intervals (CI) for endometrial cancer estimated using the multivariate Cox’s regression model from the National Health Insurance Catastrophic Illnesses Registry of Taiwan for all tamoxifen-treated breast cancer women 20–79 years who were followed up from 1998 to 2008.

Presence of endometrial cancer during the follow-up period	TMX users using Chinese medicine containing ginseng. Number of cases/person-years	TMX users not using Chinese medicine. Number of cases/person-years	TMX users using Chinese medicine containing ginseng divided by TMX users not using Chinese medicine.; Adjusted HR^* (95% CI)
Total TMX users	74/78,257	107/67,503	0.68 (0.51–0.93)
Duration of TMX treatment
<2 years	35/31,974	77/35,889	0.59 (0.39–0.88)
2–4 years	25/24,195	20/16,771	0.86 (0.47–1.56)
>4 years	14/22,088	10/14,842	0.89 (0.39–2.04)
Cumulative TMX doses
<7,500 mg	19/18,630	62/24,030	0.47 (0.28–0.79)
7,500–14,999 mg	16/13,235	14/11,636	0.91 (0.44–1.90)
15,000–29,999 mg	24/23,890	21/16,581	0.79 (0.43–1.43)
≥30,000 mg	15/22,502	10/15,257	1.04 (0.46–2.35)

Adjusted for age at breast cancer diagnosis, insured salary, insured region, diabetes, hypertension, duration of TMX treatment, and cumulative TMX doses.
TMX refers to tamoxifen.